SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, Eisenhaure T, Henrickson SE, Villani AC, Hacohen N, Abudi N, Abramovich R, Cohen JE, Peretz T, Veillette A, Lotem M.
Hajaj E, et al. Among authors: abudi n.
Elife. 2020 Mar 3;9:e52539. doi: 10.7554/eLife.52539.
Elife. 2020.
PMID: 32122464
Free PMC article.